Cintas (CTAS)
(Delayed Data from NSDQ)
$205.62 USD
-0.19 (-0.09%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $205.53 -0.09 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.62 USD
-0.19 (-0.09%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $205.53 -0.09 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Zacks News
Cintas (CTAS) Exhibits Solid Prospects, Challenges Persist
by Zacks Equity Research
Cintas (CTAS) is likely to benefit from strength across its healthcare and hygiene end markets, acquired asset and shareholder-friendly policies. Soft end markets and high-debt are concerning.
Cintas (CTAS) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cintas (CTAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Cintas (CTAS) Stock Might be a Great Pick
by Zacks Equity Research
Cintas (CTAS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Cintas (CTAS) Stock Might be a Great Pick
by Zacks Equity Research
Cintas (CTAS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cintas (CTAS) Exhibits Strong Prospects Amid Challenges
by Zacks Equity Research
Cintas (CTAS) stands to gain from strength across its healthcare and hygiene end markets, acquired asset and shareholder-friendly policies. End-market challenges and high-debt are concerning.
Cintas (CTAS) Tops on Q3 Earnings, Gives Solid Sales View
by Zacks Equity Research
Cintas' (CTAS) Q3 results reflect the impacts of lower revenues as well as a decline in costs and expenses. The company anticipates Q4 revenues to improve sequentially.
Cintas (CTAS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cintas (CTAS) delivered earnings and revenue surprises of 7.24% and 1.15%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?
Titan Machinery (TITN) to Report Q4 Earnings: What to Expect?
by Zacks Equity Research
Titan Machinery (TITN) fourth-quarter fiscal 2021 results are likely to reflect favorable agriculture market fundamentals, higher construction demand and efforts to control operating expenses.
MP Materials (MP) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
MP Materials' (MP) fourth-quarter results are likely to reflect higher production realized price owing to improved efficiency of its processing operations and higher average realized prices.
Will Cintas (CTAS) Keep Its Earnings Streak Alive in Q3?
by Zacks Equity Research
Cintas' (CTAS) Q3 earnings results to reflect the impacts of one less working day and the pandemic-related woes. The healthy demand in hygiene and healthcare markets is likely to have been appealing.
Should You Buy Cintas (CTAS) Ahead of Earnings?
by Zacks Equity Research
Cintas (CTAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Energy Fuels (UUUU) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Energy Fuels' (UUUU) fourth-quarter results are likely to reflect its decision to withhold uranium and vanadium sales until prices rise. A debt free balance sheet and cost cutting efforts will aid margins.
Cintas (CTAS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cintas (CTAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Hot Upcoming Earnings Charts
by Tracey Ryniec
Earnings season is winding down over the next 2 weeks but there are still incredible earnings charts still to come.
Why Cintas (CTAS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Cintas (CTAS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ingersoll (IR) to Post Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Ingersoll Rand's (IR) Q4 earnings are likely to have gained from solid product portfolio, the Albin Pump buyout and cost-control actions. Unfavorable product mix might have marred its performance.
Cintas (CTAS) Provides Third-Quarter Fiscal 2021 Projections
by Zacks Equity Research
Cintas (CTAS) third-quarter fiscal 2021 projections reflect the impacts of the pandemic and one less working day. Share buybacks and dividend payments are priority.
Why Is Cintas (CTAS) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Cintas (CTAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Salesforce, HSBC, Honda Motor, Cintas and MarketAxess
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, HSBC, Honda Motor, Cintas and MarketAxess
Top Research Reports for salesforce, HSBC & Honda Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), HSBC Holdings plc (HSBC) and Honda Motor Co., Ltd. (HMC).
Cintas (CTAS) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Cintas' (CTAS) Q2 results benefit from improved margin profile that offset the impact of a revenue decline. It refrains from providing projections for fiscal 2021 on the pandemic-led uncertainties.
Cintas (CTAS) Q2 Earnings Top Estimates
by Zacks Equity Research
Cintas (CTAS) delivered earnings and revenue surprises of 20.18% and -0.23%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
Q4 Earnings Season Preview
by Sheraz Mian
The consensus expectation is for total S&P 500 earnings to decline -11% in Q4 from the same period last year on essentially flat revenues. This would follow the -7% decline in Q3 and -32.2% decline in Q2...
Cintas (CTAS) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cintas' (CTAS) Q2 earnings are expected to have gained from strength across its healthcare and hygiene end markets, Doritex business and cost control actions. Coronavirus-led issues might have hurt.
Cintas (CTAS) Displays Bright Prospects, Headwinds Remain
by Zacks Equity Research
Cintas (CTAS) will benefit from strength across its healthcare and hygiene end-markets, acquired asset and shareholder-friendly policies. The coronavirus outbreak-led market downturn is concerning.